Gene test, Oncotype DX, may reveal which women with early-stage breast cancer can skip chemo

“Oncotype DX may help a lot of women avoid chemotherapy with the comfort of confidence that they do not need it. Pass the information along and follow the development in Europe and as it becomes used in the US.” Bill Chesnut, MD.

Gene test may reveal which women with early-stage breast cancer can skip chemo.

The Wall Street Journal (9/28, Winslow, Subscription Publication) reports that research presented at the European Cancer Congress in Vienna and published online in the New England Journal of Medicine suggests that a gene test known as Oncotype DX may help certain women with early-stage breast cancer skip chemotherapy.

The AP (9/28, Marchione) reports that “the test accurately identified a group of women whose cancers are so likely to respond to hormone-blocking drugs that adding chemo would do little if any good while exposing them to side effects and other health risks.” Researchers found that “women who skipped chemo based on the test had less than a 1 percent chance of cancer recurring far away, such as the liver or lungs, within the next five years.”

AMA Newsletter 9.28.15